ROS1-positive NSCLC

ROS1 fusions are rare in non-small cell lung cancer (NSCLC), but identifying these rearrangements can significantly impact patient outcomes. Comprehensive testing protocols are needed to avoid missed opportunities to detect ROS1 fusions and select appropriate targeted therapy. 

As a leading expert in the diagnosis and treatment of ROS1-positive NSCLC, Dr Maurice Pérol shares his insights and explains why comprehensive next-generation sequencing should be performed at diagnosis.

Dr Pérol then sets out the ideal clinical practice of basing treatment decisions on biomarker results to evaluate a patient for targeted therapy, before providing a clear overview of the evolving ROS1 treatment landscape. 

Clinical takeaways

• Identify every ROS1 fusion. Although rare, ROS1-positive NSCLC derives significant benefit from targeted tyrosine kinase inhibitors (TKIs) compared to chemotherapy or immunotherapy 
• Use upfront comprehensive next-generation sequencing (NGS) (ideally RNA-based) to detect ROS1 rearrangements and avoid missed opportunities for targeted therapy 
• Next-generation ROS1 TKIs overcome key resistance mutations and provide improved intracranial activity 
• Early molecular profiling enables timely access to the most effective targeted therapies and improves patient outcomes